Consolidated revenue for Q1 FY27 rose to ₹7,119.28 crore, with net profit at ₹785.55 crore. Key risks include ongoing NPPA litigation and a ₹244.37 crore exceptional item from new labour codes. Segment operations remain focused on pharmaceuticals.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.